Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Pharmacokinetic Tomography (U01 Clinical Trial Required)

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Food and Drug Administration, under the Department of Health and Human Services, is seeking to fund the research and development of non-invasive technologies to characterize how topically applied drugs reach the skin in vivo. This initiative focuses on creating quantitative tomography-based apparatus, study designs, and data analysis methods to accurately measure drug concentrations at various skin depths. The goal is to establish a sensitive and reproducible approach for monitoring cutaneous pharmacokinetics through repeated serial measurements. Ultimately, this project aims to develop a scientifically valid, in vivo pharmacokinetic approach that serves as an efficient alternative for demonstrating the bioequivalence of topical products. This forecast, categorized under NAICS code 541715, requires a clinical trial and is managed by the FDA to advance the capabilities of monitoring drug availability at or near the site of action within the skin.

General Info

FDA seeks non-invasive real-time imaging tech for quantifying topical drug penetration in skin layers.

Agency

Department Of Health And Human Services → Food And Drug Administration

Place of Performance

Not specified

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → Food And Drug Administration
Contacts1 person available
OfficeUSA
Organization / Agency
Department Of Health And Human Services → Food And Drug Administration
Office AddressUSA
Contacts

Full Description

Show more

The purpose of this funding opportunity is to support the research and development necessary to advance non-invasive (e.g., quantitative tomography-based) technologies, including the development of apparatus, methods, study designs, and methods of data analysis, to characterize and compare the rate and extent to which a topically applied drug becomes available at or near a site of action within the skin in vivo. The expectation is that the funded work will produce an accurate, sensitive and reproducible approach that rapidly measures the (relative) amount of drug present in the skin at a series of depths below the skin surface, which can be utilized to monitor the cutaneous pharmacokinetics (PK) of the drug at selected depths (e.g., in the epidermis) by repeated, serial measurements over time. The intent is to support the eventual development of an alternative, scientifically valid, in vivo cutaneous PK-based approach that can be used to efficiently demonstrate the bioequivalence (BE) of topical products. 

Similar Contracts

Same NAICS industry code

NAICS: 541715
New
Federal
ACC-DTA Commercial Solutions Opening (CSO)
Solicitation # W912CH-26-S-0001
The Army Contracting Command – Detroit Arsenal (ACC-DTA) Commercial Solutions Opening (CSO), solicitation W912CH-26-S-0001, serves as a rapid-acquisition gateway to transition cutting-edge commercial technologies into active defense programs. This vehicle supports a diverse customer base, including the Intelligence and Security Command (INSCOM) and six Portfolio Acquisition Executives, focusing on the development, integration, and sustainment of ground vehicle systems to enhance Army modernization and readiness. The CSO utilizes a streamlined, merit-based, multi-phased evaluation process consisting of solution briefs, presentations, and commercial solution proposals. Awards may be issued through 2028 as FAR Part 12 contracts or non-FAR agreements, such as Other Transaction Authority (OTA) and Cooperative Agreements. The solicitation is organized around various Areas of Interest (AoI) that address critical military needs. Key initiatives include the FALCONS prototype effort for long-range reconnaissance sensors with funding ceilings between 24 million and 30 million dollars, the TIGER Readiness and Hackathon programs for Abrams Main Battle Tank engine supply chain resilience, and requirements for Counter-Unmanned Aircraft Systems (C-UAS) detection, Mobile Camouflage Systems, and Light Tactical Trailer Heavy Chassis. Technical evaluations focus on mission viability and prototype execution, while price proposals are assessed for affordability. To be eligible for award, companies must be registered in the System for Award Management (SAM) with a Unique Entity ID and comply with the Buy American Act and Specialty Metals clauses.
W6QK Acc- Dta

POSTED

about 16 hours ago

DEADLINE

in about 2 years
View Details
NAICS: 541715
New
Federal
BAA DEVCOM AC Emerging Technologies
Solicitation # W15QKN-26-S-1AZR
The U.S. Army Combat Capabilities Development Command Armaments Center is soliciting research proposals and white papers for new and innovative technologies related to emerging weapons, munitions systems, and soldier lethality. Issued under FAR 6.102(d)(2), this Broad Agency Announcement is a continuously open solicitation effective from March 5, 2026, through March 4, 2031. The program seeks to advance the state of the art through collaborations with industry and academia, with a particular interest in scientific study and experimentation that fills technology needs across the product life cycle, including improvements in armament packaging, ammunition logistics, and micro-system architecture. The submission process is a two-stage effort beginning with a white paper, which is limited to six pages plus a cover page and biographical sketches. Offerors whose white papers are favorably evaluated may be invited to submit a full research proposal. The government prefers proposals covering a three-year period of performance with incremental funding. Awards are based on a competitive selection process evaluating overall scientific and technical merit, potential contributions to the Army mission, offeror capabilities, personnel qualifications, past performance, and proposed price. All submissions must be unclassified and adhere to strict formatting guidelines, including 12-point Times New Roman font for narrative text.
W6QK Acc-Ri-Picatinny

POSTED

about 16 hours ago

DEADLINE

in over 4 years
View Details
NAICS: 541715
New
Federal
Common Autonomous Multi-Domain Launcher (CAML)-Lite Prototype Effort
Solicitation # W50RAJ27CAML_LITE
The Common Autonomous Multi-Domain Launcher (CAML)-Lite Prototype Effort is a competitive procurement conducted under 10 U.S.C. section 4022 for the development of a mobile, optionally manned, autonomous launcher designed to increase survivability and reduce manned support for cross-domain fires. Managed by the Department of Defense, this effort utilizes Other Transaction Agreements (OTAs) and follows a two-phase structure. Phase 1 focuses on a government-sponsored prototype demonstration at Talisman Sabre 2027 in August 2027, with options for the government to acquire additional prototype units, new equipment training, and contractor logistics support. Phase 2 involves maturing selected solutions into a production-representative configuration integrated into a common CAML architecture. The procurement process begins with a Request for Solutions Brief to identify meritorious respondents, who will then be invited to submit a Request for Prototype Proposal. Key technical requirements include the use of a Modular Open Systems Approach (MOSA) to ensure interchangeable modules and common interfaces. Performers are required to assume full responsibility for international logistics and compliance for the Phase 1 demonstration and must adhere to minimum Right to Repair requirements as a condition of award. Selection for Phase 1 is based on the feasibility of the maturation path and the technical soundness of the approach, while subsequent option exercises will prioritize speed of delivery, technical performance, property rights, and the right to repair. Phase 1 OTA awards are expected by December 18, 2026, with a firm-fixed-price payment structure split between award and demonstration completion.
W6DV Peo M & S Redstone

POSTED

1 day ago

DEADLINE

in about 17 hours
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS